JP2011505356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505356A5 JP2011505356A5 JP2010535919A JP2010535919A JP2011505356A5 JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5 JP 2010535919 A JP2010535919 A JP 2010535919A JP 2010535919 A JP2010535919 A JP 2010535919A JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99126507P | 2007-11-30 | 2007-11-30 | |
| PCT/SE2008/051370 WO2009070116A1 (en) | 2007-11-30 | 2008-11-28 | A quinoline derivative acting as a p2x7-receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505356A JP2011505356A (ja) | 2011-02-24 |
| JP2011505356A5 true JP2011505356A5 (enExample) | 2012-02-02 |
Family
ID=40676391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535919A Withdrawn JP2011505356A (ja) | 2007-11-30 | 2008-11-28 | Ｐ２ｘ７受容体アンタゴニストとして作用するキノリン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8106073B2 (enExample) |
| EP (1) | EP2225222B1 (enExample) |
| JP (1) | JP2011505356A (enExample) |
| AR (1) | AR069508A1 (enExample) |
| AT (1) | ATE524458T1 (enExample) |
| ES (1) | ES2370960T3 (enExample) |
| PE (1) | PE20091036A1 (enExample) |
| TW (1) | TW200932229A (enExample) |
| WO (1) | WO2009070116A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008114002A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| PH12012501222A1 (en) * | 2009-12-17 | 2012-11-05 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| KR101995088B1 (ko) | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| NZ628910A (en) | 2012-01-20 | 2016-02-26 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
| KR102222220B1 (ko) | 2013-01-22 | 2021-03-03 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| AU2015269598B2 (en) * | 2014-06-05 | 2019-11-14 | Merck Patent Gmbh | Novel quinoline derivatives and their use in neurodegenerative diseases |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| IL53441A0 (en) | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| US4751292A (en) | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| ATE148098T1 (de) | 1991-02-21 | 1997-02-15 | Sankyo Co | Benzolderivate zum fördern der produktion des nervenwachstumsfaktors |
| PT720601E (pt) | 1993-08-10 | 2001-02-28 | Black James Foundation | Ligandos de receptores de gastrina e cck |
| RO114445B1 (ro) | 1994-05-27 | 1999-04-30 | Smithkline Beecham S.P.A. | Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament |
| AR004735A1 (es) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| NZ332341A (en) | 1996-05-20 | 2000-05-26 | Darwin Discovery Ltd | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
| FR2761358B1 (fr) | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO1999026927A2 (en) | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| HUP0202214A3 (en) | 1999-04-09 | 2002-12-28 | Astrazeneca Ab | Adamantane derivatives, preparation and use thereof |
| CN1361768A (zh) | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| WO2001037826A1 (en) | 1999-11-26 | 2001-05-31 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| RU2347570C2 (ru) | 2001-07-02 | 2009-02-27 | Н.В.Органон | Тетрагидрохинолиновые производные |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| US20080058309A1 (en) | 2006-07-27 | 2008-03-06 | Astrazeneca Ab | Novel Compounds 171 |
| WO2008114002A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
-
2008
- 2008-11-26 US US12/324,397 patent/US8106073B2/en not_active Expired - Fee Related
- 2008-11-26 PE PE2008001976A patent/PE20091036A1/es not_active Application Discontinuation
- 2008-11-28 ES ES08855156T patent/ES2370960T3/es active Active
- 2008-11-28 WO PCT/SE2008/051370 patent/WO2009070116A1/en not_active Ceased
- 2008-11-28 EP EP08855156A patent/EP2225222B1/en not_active Not-in-force
- 2008-11-28 AT AT08855156T patent/ATE524458T1/de not_active IP Right Cessation
- 2008-11-28 TW TW097146304A patent/TW200932229A/zh unknown
- 2008-11-28 JP JP2010535919A patent/JP2011505356A/ja not_active Withdrawn
- 2008-11-28 AR ARP080105220A patent/AR069508A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006182786A5 (enExample) | ||
| JP2009542613A5 (enExample) | ||
| JP2009537498A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2011518202A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2009543860A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
| JP2015502974A5 (enExample) | ||
| TWI455938B (zh) | 碳酸啶衍生物及其醫藥組成物 | |
| JP2012513390A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| JP2019529460A5 (enExample) | ||
| MXPA05013856A (es) | Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad. | |
| JP2012144537A5 (enExample) |